2022-28549. National Heart, Lung, and Blood Institute; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Heart, Lung, and Blood Advisory Council.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The open session will be videocast and can be accessed from the NIH Videocast website https://www.nhlbi.nih.gov/​about/​advisory-and-peer-review-committees/​advisory-council.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Heart, Lung, and Blood Advisory Council.

Date: February 8, 2023.

Closed: 09:00 a.m. to 10:00 a.m.

Agenda: To Review and Evaluate Grant Applications.

Place: National Institutes of Health, Porter Neuroscience Research Center, 35 Convent Drive, Bethesda, MD 20890.

Open: 10:00 a.m. to 2:00 p.m.

Agenda: To Discuss Program Policies and Issues.

Place: National Institutes of Health, Porter Neuroscience Research Center, 35 Convent Drive, Bethesda, MD 20890.

Videocast link: The meeting will be videocast and can be accessed from the NIH Videocast. https://www.nhlbi.nih.gov/​about/​advisory-and-peer-review-committees/​advisory-council. Please note, the link to the videocast meeting will be posted within a week of the meeting date.

Contact Person: Laura K. Moen, Ph.D., Director, Division of Extramural Research Activities, National Heart, Lung, and Blood Institute, National Institutes of Health, 6705 Rockledge Drive, Room 206-Q, Bethesda, MD 20892, 301-827-5517, [e-mail]

Any member of the public interested in presenting oral comments to the committee may notify the Contact Person listed on this notice at least 10 days in advance of the meeting. Interested individuals and representatives of organizations may submit a letter of intent, a brief description of the organization represented, and a short description of the oral presentation. Only one representative of an organization may be allowed to present oral comments and if accepted by the committee, presentations may be limited to five minutes. Both printed and electronic copies are requested for the record. In addition, any interested person may file written comments with the committee by forwarding their statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has procedures at https://www.nih.gov/​about-nih/​visitor-information/​campus-access-security for entrance into on-campus and off-campus facilities. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors attending a meeting on campus or at an off-campus federal facility will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

Additional Health and Safety Guidance: Before attending a meeting at an NIH facility, it is important that visitors review the NIH COVID-19 Safety Plan at https://ors.od.nih.gov/​sr/​dohs/​safety/​NIH-covid-19-safety-plan/​Pages/​default.aspx and the NIH testing and assessment web page at https://ors.od.nih.gov/​sr/​dohs/​safety/​NIH-covid-19-safety-plan/​COVID-assessment-testing/​Pages/​visitor-testing-requirement.aspx for information about requirements and procedures for entering NIH facilities, especially when COVID-19 community levels are medium or high. In addition, the Safer Federal Workforce website has FAQs for visitors at https://www.saferfederalworkforce.gov/​faq/​visitors/​. Please note that if an individual has a COVID-19 diagnosis within 10 days of the meeting, that person must attend virtually. (For more information please read NIH's Requirements for Persons after Exposure at https://ors.od.nih.gov/​sr/​dohs/​safety/​NIH-covid-19-safety-plan/​COVID-assessment-testing/​Pages/​persons-after-exposure.aspx and What Happens When Someone Tests Positive at https://ors.od.nih.gov/​sr/​dohs/​safety/​NIH-covid-19-safety-plan/​COVID-assessment-testing/​Pages/​test-positive.aspx. Anyone from the public can attend the open portion of the meeting virtually via the NIH Videocasting website ( http://videocast.nih.gov). Please continue checking these websites, in addition to the committee website listed below, for the most up to date guidance as the meeting date approaches.

Information is also available on the Institute's/Center's home page: www.nhlbi.nih.gov/​meetings/​nhlbac/​index.htm, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: December 28, 2022.

David W. Freeman,

Program Analyst, Office of Federal Advisory Committee Policy.